Who are Recombinant Human Coagulation FVIII's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xyntha, Moroctocog alfa (AF-CC), Efmoroctocog Alfa Injection [Eloctate], OBIZUR, Kogenate (BAY14-2222), Coagulation Factor VIII.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-human-coagulation-fviii.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Recombinant Human Coagulation FVIII — Competitive Intelligence Brief

Recombinant Human Coagulation FVIII (Recombinant Human Coagulation FVIII) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Coagulation factor replacement therapy. Area: Hematology.

marketed Coagulation factor replacement therapy Coagulation Factor VIII Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Recombinant Human Coagulation FVIII (Recombinant Human Coagulation FVIII) — Sinocelltech Ltd.. Recombinant human coagulation factor VIII replaces deficient or dysfunctional Factor VIII to restore the intrinsic coagulation pathway and enable normal blood clot formation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Recombinant Human Coagulation FVIII TARGET	Recombinant Human Coagulation FVIII	Sinocelltech Ltd.	marketed	Coagulation factor replacement therapy	Coagulation Factor VIII
Xyntha	xyntha	Pfizer	marketed	Recombinant protein therapy	Coagulation factor VIII
Moroctocog alfa (AF-CC)	Moroctocog alfa (AF-CC)	Pfizer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Efmoroctocog Alfa Injection [Eloctate]	Efmoroctocog Alfa Injection [Eloctate]	The League of Clinical Research, Russia	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII (intrinsic tenase complex)
OBIZUR	OBIZUR	Baxalta now part of Shire	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Kogenate (BAY14-2222)	Kogenate (BAY14-2222)	Bayer	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Coagulation Factor VIII	Coagulation Factor VIII	Beijing Children's Hospital	marketed	Coagulation factor replacement	Coagulation Factor VIII (antihemophilic factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Coagulation factor replacement therapy class)

Hoffmann-La Roche · 2 drugs in this class
Genzyme, a Sanofi Company · 1 drug in this class
Octapharma · 1 drug in this class
Sinocelltech Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant Human Coagulation FVIII — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-coagulation-fviii. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab